T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers

BACKGROUND: Disease modifying therapies for multiple sclerosis (MS) can impair the specific immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Specifically, it is recognized that ocrelizumab reduces or abrogates anti-SARS-CoV-2 antibody production after natural infectio...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mult Scler Relat Disord
Главные авторы: Iannetta, Marco, Landi, Doriana, Cola, Gaia, Malagnino, Vincenzo, Teti, Elisabetta, Fraboni, Daniela, Buccisano, Francesco, Grelli, Sandro, Coppola, Luigi, Campogiani, Laura, Andreoni, Massimo, Marfia, Girolama Alessandra, Sarmati, Loredana
Формат: Artigo
Язык:Inglês
Опубликовано: Published by Elsevier B.V. 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8291995/
https://ncbi.nlm.nih.gov/pubmed/34418737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2021.103157
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы